Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CORAL GABLES, FLA., JULY 28, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF BIPIN DALMIA, PHD, MBA, AS CHIEF BUSINESS OFFICER. BIPIN WILL LEAD RELMADA'S CORPORATE STRATEGY, COMMERCIAL PLANNING, AND BUSINESS DEVELOPMENT ACTIVITIES, REPORTING DIRECTLY TO CHIEF EXECUTIVE OFFICER SERGIO TRAVERSA.

RELMADA THERAPEUTICS APPOINTS URO-ONCOLOGY LEADER BIPIN DALMIA AS CHIEF BUSINESS OFFICER

CORAL GABLES, FLA., JULY 16, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 6, 2026 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND RECENT BUSINESS PROGRESS.

RELMADA THERAPEUTICS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON THURSDAY, AUGUST 6, 2026

CORAL GABLES, FLA., JUNE 29, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED THAT THE COMPANY JOINED THE RUSSELL 2000 INDEX AND THE RUSSELL 3000 INDEX EFFECTIVE AFTER THE U.S. MARKET CLOSED ON JUNE 26, 2026, AS PART OF THE RUSSELL INDEXES RECONSTITUTION.

RELMADA THERAPEUTICS JOINS RUSSELL 2000 AND RUSSELL 3000 INDEXES

CORAL GABLES, FLA., JUNE 11, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF MICHAEL QUIRK, PHD, AS SENIOR ADVISOR  SEPRANOLONE PROGRAM. DR. QUIRK'S DEEP EXPERTISE IN CNS TRANSLATIONAL SCIENCE, NEUROACTIVE STEROID BIOLOGY, AND CLINICAL DEVELOPMENT WILL BE INSTRUMENTAL IN ADVANCING SEPRANOLONE, RELMADA'S GABAA RECEPTOR MODULATOR PROGRAM TARGETING PRADER-WILLI SYNDROME AND OTHER CNS INDICATIONS.

RELMADA THERAPEUTICS APPOINTS CNS DRUG DEVELOPMENT VETERAN MICHAEL QUIRK AS SENIOR ADVISOR FOR SEPRANOLONE PROGRAM

CORAL GABLES, FLA., MAY 28, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED THAT SERGIO TRAVERSA, CHIEF EXECUTIVE OFFICER, AND MAGED SHENOUDA, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE BEING HELD IN NEW YORK, NY, FROM JUNE 2-4, 2026.

RELMADA THERAPEUTICS TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

POSITIVE 12-MONTH PHASE 2 DATA FOR NDV-01 DEMONSTRATED A 95% COMPLETE RESPONSE (CR) RATE AT ANY TIME AND A DURABLE 76% CR RATE AT 12 MONTHS IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC), AND A 94% CR RATE AT ANY TIME AND A DURABLE 80% CR RATE AT 12 MONTHS IN THE BCG-UNRESPONSIVE SUBPOPULATION, REINFORCING BEST-IN-CLASS POTENTIAL IN NMIBC ON TRACK TO INITIATE PHASE 3 RESCUE REGISTRATIONAL PROGRAM IN SECOND LINE (2L) BCG-UNRESPONSIVE AND ADJUVANT INTERMEDIATE-RISK NMIBC IN MID-2026 FILED PROVISIONAL PATENT APPLICATION WITH THE USPTO IN APRIL 2026 COVERING NDV-01 PHARMACEUTICAL FORMULATIONS AND METHODS OF TREATMENT; IF ISSUED, PATENTS CLAIMING PRIORITY TO THE PROVISIONAL FILING WOULD HAVE A TERM UNTIL APRIL 2047 RELMADA WILL FEATURE TWO NDV-01 PRESENTATIONS AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING (AUA2026), HIGHLIGHTING THE 12-MONTH PHASE 2 DATA AND THE PHASE 3 RESCUE PROGRAM DESIGN AND RATIONALE CASH BALANCE OF $234.0 MILLION AS OF MARCH 31, 2026 EXPECTED TO FUND OPERATIONS THROUGH 2029, INCLUDING COMPLETION OF THE NDV-01 PHASE 3 RESCUE PROGRAM MANAGEMENT TO HOST A CONFERENCE CALL AND WEBCAST TODAY AT 4:30 PM ET CORAL GABLES, FLA., MAY 12, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026 AND PROVIDED A CORPORATE UPDATE.

RELMADA THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CORAL GABLES, FLA., MAY 06, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON TUESDAY, MAY 12, 2026 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND RECENT BUSINESS PROGRESS.

RELMADA THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON TUESDAY, MAY 12, 2026

CORAL GABLES, FLA., MAY 05, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF TWO ABSTRACTS RELATED TO NDV-01 AT THE AMERICAN UROLOGY ASSOCIATION (AUA2026), TAKING PLACE FROM MAY 15-18 TH IN WASHINGTON D.C.

RELMADA THERAPEUTICS TO PRESENT NDV-01 ABSTRACTS AT AUA2026

CORAL GABLES, FLA., MARCH 19, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED AUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED A CORPORATE UPDATE HIGHLIGHTING SIGNIFICANT PROGRESS ACROSS ITS PIPELINE.

RELMADA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATE

CORAL GABLES, FLA., MARCH 12, 2026 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, MARCH 19, 2026 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2025, AND RECENT BUSINESS PROGRESS.

Relmada Therapeutics, Inc.

RLMD

Price

Financial Reports

No items found.

Press Releases

Relmada Therapeutics, Inc.

RLMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RLMD